160 related articles for article (PubMed ID: 9546683)
21. Dialysis-related carpal tunnel syndrome in the past 40 years.
Hatano M; Kitajima I; Yamamoto S; Nakamura M; Isawa K; Suwabe T; Hoshino J; Sawa N; Ubara Y
Clin Exp Nephrol; 2022 Jan; 26(1):68-74. PubMed ID: 34415463
[TBL] [Abstract][Full Text] [Related]
22. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: comparative study of advanced glycation end products, carboxymethyllysine and pentosidine.
Uchimura T; Motomiya Y; Okamura H; Hashiguchi T; Miura M; Uji Y; Iwamoto H; Maruyama I
Nephron; 2002 Apr; 90(4):401-7. PubMed ID: 11961398
[TBL] [Abstract][Full Text] [Related]
23. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.
Sanaka T; Funaki T; Tanaka T; Hoshi S; Niwayama J; Taitoh T; Nishimura H; Higuchi C
Nephron; 2002 May; 91(1):64-73. PubMed ID: 12021521
[TBL] [Abstract][Full Text] [Related]
24. Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis.
Odetti P; Monacelli F; Storace D; Robaudo C; Rossi S; Deferrari G; Barreca T
Horm Metab Res; 2006 Dec; 38(12):817-20. PubMed ID: 17163357
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome.
Tagami A; Tomita M; Adachi S; Tsuda K; Yamada S; Chiba K; Okazaki N; Yonekura A; Tsujimoto R; Kajiyama S; Matsubayashi S; Miyamoto T; Mochizuki Y; Ohba K; Osaki M
J Bone Miner Metab; 2020 Jan; 38(1):78-85. PubMed ID: 31414282
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.
Matsuo K; Ikizler TA; Hoover RL; Nakamoto M; Yasunaga C; Pupim LB; Hakim RM
Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049
[TBL] [Abstract][Full Text] [Related]
27. Daily haemodialysis improves indices of protein glycation.
Floridi A; Antolini F; Galli F; Fagugli RM; Floridi E; Buoncristiani U
Nephrol Dial Transplant; 2002 May; 17(5):871-8. PubMed ID: 11981076
[TBL] [Abstract][Full Text] [Related]
28. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Honda H; Hosaka N; Aoshima Y; Hirai Y; Michihata T; Akizawa T
Clin Exp Hypertens; 2012; 34(1):17-23. PubMed ID: 22149003
[TBL] [Abstract][Full Text] [Related]
29. Direct quantification of pentosidine in urine and serum by HPLC with column switching.
Takahashi M; Hoshino H; Kushida K; Kawana K; Inoue T
Clin Chem; 1996 Sep; 42(9):1439-44. PubMed ID: 8787701
[TBL] [Abstract][Full Text] [Related]
30. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
31. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
[TBL] [Abstract][Full Text] [Related]
32. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy.
Miyata T; Ueda Y; Yoshida A; Sugiyama S; Iida Y; Jadoul M; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Mar; 51(3):880-7. PubMed ID: 9067925
[TBL] [Abstract][Full Text] [Related]
33. The advanced glycation endproduct pentosidine and monocyte activation in uremia.
Friedlander MA; Witko-Sarsat V; Nguyen AT; Wu YC; Labrunte M; Verger C; Jungers P; Descamps-Latscha B
Clin Nephrol; 1996 Jun; 45(6):379-82. PubMed ID: 8793229
[TBL] [Abstract][Full Text] [Related]
34. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients.
Zoccali C; Mallamaci F; Asahia K; Benedetto FA; Tripepi G; Tripepi R; Nicocia G; Buemi M; Miyata T
J Nephrol; 2001; 14(4):293-8. PubMed ID: 11506253
[TBL] [Abstract][Full Text] [Related]
35. Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010.
Hoshino J; Yamagata K; Nishi S; Nakai S; Masakane I; Iseki K; Tsubakihara Y
Nephrol Dial Transplant; 2016 Apr; 31(4):595-602. PubMed ID: 26206763
[TBL] [Abstract][Full Text] [Related]
36. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.
Suliman ME; Heimbürger O; Bárány P; Anderstam B; Pecoits-Filho R; Rodríguez Ayala E; Qureshi AR; Fehrman-Ekholm I; Lindholm B; Stenvinkel P
J Am Soc Nephrol; 2003 Jun; 14(6):1614-22. PubMed ID: 12761263
[TBL] [Abstract][Full Text] [Related]
37. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
Misselwitz J; Franke S; Kauf E; John U; Stein G
Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
[TBL] [Abstract][Full Text] [Related]
38. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients.
Furuya R; Kumagai H; Miyata T; Fukasawa H; Isobe S; Kinoshita N; Hishida A
Clin Exp Nephrol; 2012 Jun; 16(3):421-6. PubMed ID: 22160670
[TBL] [Abstract][Full Text] [Related]
39. Quantification of the cross-link pentosidine in serum from normal and uremic subjects.
Takahashi M; Kushida K; Kawana K; Ishihara C; Denda M; Inoue T; Horiuchi K
Clin Chem; 1993 Oct; 39(10):2162-5. PubMed ID: 8403403
[TBL] [Abstract][Full Text] [Related]
40. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
Hricik DE; Wu YC; Schulak A; Friedlander MA
Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
